MTHFR and Recurrent Pregnancy Loss Explained
Does an MTHFR variant actually explain recurrent pregnancy loss?
Current major society guidelines (ASRM, ACOG, ESHRE, RCOG) recommend against routine MTHFR testing or treatment for recurrent loss — heterozygous variants are common and don't reliably distinguish RPL patients from the general population. Switching to methylfolate remains a reasonable, low-risk choice for other reasons, but it shouldn't carry outsized weight as 'the' explanation for loss.
MTHFR and Recurrent Pregnancy Loss: What the Evidence Actually Shows
After recurrent pregnancy loss, it's common to end up with an extensive workup — dozens of blood tests — and find only one mild abnormality, or nothing definitive at all. In that gap between "something must explain this" and "the tests came back essentially normal," something comes up constantly in patient communities: MTHFR gene variants. This deserves an honest look, because the evidence on it is more specific — and in some ways more limited — than online discussion often suggests.
MTHFR and Pregnancy Loss: What the Evidence Actually Shows
MTHFR (methylenetetrahydrofolate reductase) is an enzyme involved in folate metabolism and homocysteine regulation. Certain variants, including the commonly discussed A1298C and C677T, are extremely common in the general population — carrying one doesn't make someone unusual, and for a long time, these variants were suspected to contribute to pregnancy loss through elevated homocysteine and clotting-related mechanisms.
The evidence has moved substantially since that theory took hold, and it's worth knowing where it actually stands now. ASRM's most recent (2026) committee opinion on recurrent pregnancy loss explicitly recommends against routine testing or treatment for MTHFR variants. This is consistent with ACOG, ESHRE, and RCOG guidance, all of which have moved away from recommending MTHFR testing as part of a standard recurrent loss workup, based on evidence that these variants — heterozygous ones especially — don't reliably distinguish RPL patients from the general population. A large randomized controlled trial (ALIFE2) specifically testing low-molecular-weight heparin for inherited thrombophilias, including MTHFR variants, found no difference in pregnancy loss, stillbirth, or live birth rates between treatment and placebo groups. In short: heterozygous MTHFR variants are common, usually don't affect pregnancy outcomes, and current major guidelines don't support either routine testing or treatment based on MTHFR status alone.
This doesn't mean addressing folate metabolism has no value at all — many clinicians reasonably recommend methylfolate (5-MTHF) over folic acid for MTHFR variant carriers, since the biological rationale (folic acid requires enzymatic conversion that may be less efficient in some variant carriers) is sound, and it's a low-risk substitution. Some patients also report genuine improvements in unrelated chronic symptoms after making this switch. But it's important to separate two different claims: "this substitution may support general health and is low-risk to make" is reasonable; "this variant is the explanation for recurrent pregnancy loss" is not well supported by current evidence, and shouldn't carry outsized weight in decisions about further testing or treatment.
When the Workup Comes Back Clear: Understanding "Unexplained" RPL
It's worth naming directly: after an extensive Recurrent Pregnancy Loss workup, finding no clear cause - or only a minor, likely-unrelated finding - is common, not a sign that something was missed. Unexplained RPL is a real, well-documented clinical category. This isn't the same as "nothing is wrong" - it reflects the genuine limits of current diagnostic tools, not a failure of the evaluation. It also doesn't mean further treatment, including IVF with genetic testing of embryos, won't help; it means the specific mechanism may not be identifiable with current testing, which is its own frustrating reality but a different one than "the answer was missed."
The Bottom Line
This deserves serious, honest engagement — something we prioritize with every patient we see from Huntington and across Long Island — rather than either dismissal or overpromising. Heterozygous MTHFR variants are common and, per current major society guidelines, are not established as a driver of recurrent pregnancy loss - though addressing folate metabolism with methylfolate remains a reasonable, low-risk choice for other reasons. This should not discourage anyone from taking their fertility seriously; rather, keep an open mind and always do no harm. Related reading: laparoscopy after recurrent pregnancy loss.
This article is for general educational purposes and isn't a substitute for individualized guidance from your own physician or reproductive endocrinologist. Testing, supplementation, and treatment decisions related to recurrent pregnancy loss or ovarian reserve should be made directly with your care team.
East to West Fertility, is a metabolic and immune-focused fertility practice in Huntington, NY, serving Long Island, NYC, and beyond. We help patients navigate recurrent pregnancy loss workups and evidence-based (and honestly-assessed emerging) options for ovarian reserve support, alongside your existing REI care. Learn more about our Metabolic & Immune Fertility Evaluation at easttowestfertility.com or call 631-416-4940.
References:
"Recurrent pregnancy loss: a committee opinion (2026)." American Society for Reproductive Medicine.
"Guideline No. 464: Recurrent Pregnancy Loss." Includes ALIFE2 RCT findings on inherited thrombophilias and LMWH.
"ASRM releases 2026 guidelines on managing recurrent pregnancy loss."
